Hillsdale Investment Management Inc. Has $577,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Hillsdale Investment Management Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 33.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,992 shares of the company's stock after selling 2,000 shares during the period. Hillsdale Investment Management Inc.'s holdings in Johnson & Johnson were worth $577,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after acquiring an additional 329,473 shares during the period. United Bank raised its holdings in shares of Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company's stock valued at $614,000 after buying an additional 202 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $365,000. Algert Global LLC bought a new position in Johnson & Johnson in the 3rd quarter worth approximately $721,000. Finally, Cahill Financial Advisors Inc. increased its position in Johnson & Johnson by 12.8% in the 3rd quarter. Cahill Financial Advisors Inc. now owns 4,038 shares of the company's stock valued at $654,000 after acquiring an additional 459 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Remove Ads

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

JNJ stock traded up $1.82 during mid-day trading on Thursday, hitting $163.54. 2,373,586 shares of the company were exchanged, compared to its average volume of 7,067,792. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The business has a 50 day simple moving average of $158.04 and a 200-day simple moving average of $156.18. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock has a market capitalization of $394.10 billion, a PE ratio of 24.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.29 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. Johnson & Johnson's payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.